Date: March 5, 2013
Location: Princeton Marriott (Princeton, NJ)

Alzheimer’s disease, the most common neurodegenerative disease among the elderly, represents one of the most costly diseases in the US. As of today no cure exists. Currently there are five FDA approved drugs that treat the symptoms which only have a slowing effect on the disease progression. Newer approaches are trying to modify the disease process itself. Formation and deposition of beta-amyloid, formation of phosho-tau and neurofibrillary tangles and inflammation accompanying the plaque and tangle formation are representing the main targets of current strategies. The event will provide an overview of the current status of the drug discovery process in academia and the pharmaceutical industry. In addition, outcome of recent and ongoing clinical studies will be discussed.


• Update on Drug Discovery and Development for Alzheimer’s Disease (Howard Fillit)

• Monoclonal Antibodies and Other Approaches to Therapy for tau Pathology (Peter Davies)